Product

Portfolio Intelligence Portside Congress trades Super-investors Economic calendar Earnings calendar Pricing

Company

About FAQs Contact Create account

Legal

Privacy Terms Portside rules

JAZZ

Jazz Pharmaceuticals plc

COMMON STOCK · NASDAQ

Loading evidence for JAZZ

Price and daily change

Earnings4 Nov 2026

52-week rangeSign inDay rangeSign in

Market cap: Sign in
Volume: Sign in
Beta: Sign in
Shares float: Sign in
Short interest: 7.12%
P/E (fwd): Sign in
PEG (fwd): Sign in

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Create free account

Overview Statistics Statements Dividends🔒Momentum🔒Quant🔒Fair Value🔒Earnings Analysts🔒Insiders Smart Money Options🔒Insights🔒

Trading information

Beta: Sign in
Shares outstandingAs of 2026-07-27 · filed common shares: 64.91M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 3.14%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 7.12%
Short ratioDays to cover, as published by FINRA: 3.68
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 61.10%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 68.70%
Avg volume (10D)

See the full stock page

Prices, charts, ranges, valuation ratios, dividends, momentum and analyst estimates are licensed for signed-in members. A free account opens every stock, fund and crypto page.

Create free account

Source: SEC filings. Information and analytics, not investment advice.

Rev growth (fwd)

Avg volume (3 months)

Profitability

Gross margin: —
Operating marginTTM to Jun 26: 19.49%
Net margin: —
EBITDA marginFY Dec 25: -9.11%
Return on equityNet income (TTM to Jun 26) ÷ average shareholders equity: 22.11%
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: 8.54%

Growth

Revenue growth (annual YoY): 4.88%
Revenue growth (latest qtr YoY): 15.55%
Revenue growth (fwd): Sign in
Net income growth (annual YoY)FY Dec 25 vs FY Dec 24: -163.58%
Net income growth (latest qtr YoY): —
EPS growth (fwd): Sign in
Net income growth (QoQ): -34.22%

Valuation

Market cap: Sign in
Enterprise value: Sign in
P/E: Sign in
P/E (fwd): Sign in
PEG: Sign in
PEG (fwd): Sign in
Price / book: Sign in
Price / sales

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPSDiluted, TTM to Jun 26

14.61

EPS (fwd)

Financial health

Cash & equivalentsas of Jun 26: $1.61B
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $4.39B
Debt / equityas of Jun 26: 91.53%
Current ratioas of Jun 26: 1.78
Quick ratio(Cash + marketable securities + receivables) ÷ current liabilities, as of Jun 26: 1.12
Operating cash flowTTM to Jun 26: $1.66B
Free cash flowUnadjusted FCF = CFO − capex · TTM to Jun 26: $1.59B
TTM revenue / diluted shareDiluted, TTM to Jun 26: 71.55

JAZZ stock Statistics — Jazz Pharmaceuticals plc filings, insiders & smart money · Instaport